Daniel Yerace
Förmögenhet: 339 254 $ per 2026-07-31
Förmögenhet: 339 254 $ per 2026-07-31
Daniel Yerace is the founder of Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. Mr. Yerace is currently Director & Vice President-Operations at Coeptis Therapeutics Holdings, Inc. since 2022.
Formerly, Mr. Yerace was Senior Director-Global Supply Chain at Kadmon Pharmaceuticals LLC.
Mr. Yerace completed undergraduate and MBA degrees at Waynesburg University.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
0,14 % | 2026-02-11 | 70 531 ( 0,14 % ) | 339 254 $ | 2026-07-31 |
| Företag | Position | Start |
|---|---|---|
| NAERODYNAMICS INC | Grundare | - |
Coeptis Pharmaceuticals, Inc.
Coeptis Pharmaceuticals, Inc. BiotechnologyHealth Technology Manufactures biopharmaceutical products | Grundare | - |
| Företag | Position | Slut |
|---|---|---|
| COEPTIS THERAPEUTICS | Verksamhetschef | - |
Kadmon Pharmaceuticals LLC
Kadmon Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Företagsledare/Principal | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 5 |
|---|---|
Coeptis Therapeutics, Inc.
Coeptis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and supplies novel therapy products for cancer patients | Health Technology |
Waynesburg College
Waynesburg College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kadmon Pharmaceuticals LLC
Kadmon Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Health Technology |
Coeptis Pharmaceuticals, Inc.
Coeptis Pharmaceuticals, Inc. BiotechnologyHealth Technology Manufactures biopharmaceutical products | Health Technology |
Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company developing innovative cell therapy platforms for patients with cancer | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån